Tag Archives: biopharma

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIF2012 Company Snapshot: Profil Institute for Translational Medicine

profil_trans_med

For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room.   Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

New Rare Disease Miniseries

roulette

Calling all biopharma researchers! Morning show “The Balancing Act” is producing a miniseries called “Roulette Wheel of Rare and Genetic Diseases,” and they are looking for pharmaceutical partners to help educate their audience. The series is working with the Global Genes Project to help educate patients and their families about new research, clinical trials, and government policies that affect those with a rare disease. Patient groups are already excited about this opportunity to spread awareness- take Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , ,

Nasdaq Biotech Index re-ranking for next Monday

Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched Nasdaq Biotechnology Index (NBI). This Monday (May 23rd), six companies will be added to the Nasdaq Biotech index and two will be removed. The additions are Achillion Pharmaceuticals (ACHN), AVEO Pharmaceuticals (AVEO), Columbia Laboratories (CBRX), ISTA Pharmaceuticals (ISTA), Pacific Biosciences (PACB) and Zalicus (ZLCS). The two companies to be removed from the NBI are Biodel (BIOD) and China Sky One Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,